Zenith Capital (Zenith Capital) Selling and Marketing Expense : $ Mil (TTM As of . 20)

View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital Selling and Marketing Expense?

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. Zenith Capital's Selling and Marketing Expense for the three months ended in . 20 was $0.00 Mil. Zenith Capital does not have enough years/quarters to calculate the Selling and Marketing Expense for the trailing twelve months (TTM) ended in . 20.

Zenith Capital Selling and Marketing Expense Historical Data

The historical data trend for Zenith Capital's Selling and Marketing Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital Selling and Marketing Expense Chart

Zenith Capital Annual Data

Trend

Selling and Marketing Expense

Zenith Capital Quarterly Data

Selling and Marketing Expense

Zenith Capital Selling and Marketing Expense Calculation

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services.

Zenith Capital Selling and Marketing Expense Related Terms

Thank you for viewing the detailed overview of Zenith Capital's Selling and Marketing Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenith Capital (Zenith Capital) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » Selling and Marketing Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

300, 4820 RIchard Road SW, Calgary, AB, CAN, T3E 6L1

Website

Zenith Capital Corp is a biotechnology investment company. The company operates through its wholly-owned subsidiary Zenith Epigenetics Ltd. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics. The company is developing various novel combinations of BET inhibitors with other targeted agents. Its lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) in collaboration with Astellas and Newsoara and in metastatic triple-negative breast cancer.

Zenith Capital (Zenith Capital) Headlines

No Headlines